PTC Inc. has recently released its 10-K report, detailing its financial performance for the fiscal year ending September 30, ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...

Currently, PTC Therapeutics has an average volume of 688.2K. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks ...

This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.

The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...

PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...

Raising and narrowing 2024 guidance ranges: Adjusted EBITDA of $750 to $780 million and Adjusted Free Cash Flow of $265 to $285 million. Reaffirming 2025 guidance ranges: Adjusted EBITDA of $925 to $1 ...

Transformers & Rectifiers(India)Ltd.(down 5.00%), PTC India Ltd.(down 4.62%), Suzlon Energy Ltd.(down 4.46%), Tata Power ...

Q3 marks the largest bookings in Ondas' history$14.4 million in purchase orders were from a major military customer for the Iron Drone Raider and Optimus System autonomous drone platformsIron Drone Ra ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...